As previously reported, Raymond James analyst Jayson Bedford upgraded Masimo (MASI) to Outperform from Market Perform with a $170 price target Estimates are expected to trend higher and the Masimo story is “much cleaner without Consumer, which makes it tougher for us to stay neutral,” the analyst tells investors. The firm’s core healthcare revenue assumptions are below consensus, but the firm expects Masimo to “evolve into a unique margin expansion story,” and believes “earnings power” will garner more attention, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MASI:
- Masimo upgraded to Outperform from Market Perform at Raymond James
- Masimo price target raised to $171 from $160 at Wells Fargo
- Masimo Corp. Reports Strong Q3 2024 Performance
- Masimo Reports Strong Q3 2024 Financial Results
- Masimo raises FY24 EPS view to $3.95-$4.10 from $3.80-$4.00
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
